Expertise in
2
conditions

Ather M. Siddiqi

Oxford, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Oxford, ENG, GB 

Overview

Ather Siddiqi practices practicing medicine in Oxford, United Kingdom.

Siddiqi is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Alpha-1 Antitrypsin Deficiency (AATD), Subcutaneous Emphysema, Emphysema, and Idiopathic Pulmonary Fibrosis.

They are actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 7 clinical trials.

Locations

Oxford, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Enrollment Status: Recruiting
Publish Date: August 12, 2026
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Completed
Publish Date: May 05, 2026
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency
A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency
Enrollment Status: Completed
Publish Date: December 12, 2025
Intervention Type: Biological
Study Drugs: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Biological
Study Phase: Phase 3
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 6 Less Clinical Trials

5 Total Publications

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).
A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).
Journal: The bone & joint journal
Published: June 09, 2026

Frequently Asked Questions about Ather M. Siddiqi

Is Ather M. Siddiqi a top-rated expert for Alpha-1 Antitrypsin Deficiency (AATD)?

MediFind is an objective health platform that identifies experts based on real-world data. Ather M. Siddiqi is classified as an Advanced expert for Alpha-1 Antitrypsin Deficiency (AATD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ather M. Siddiqi participate in research or clinical trials?

Yes. Ather M. Siddiqi has published 5 articles and abstracts on conditions like Alpha-1 Antitrypsin Deficiency (AATD). You can view a list of Ather M. Siddiqi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Siddiqi's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile